AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17015541 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphtheria-tetanus-acellular pertussis vaccine
Number of subjects: 12
Study 17015541 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-antigen content diphtheria-tetanus-acellular pertussis vaccine
Number of subjects: 12
Study 17015541 — intervention group
Group type: COMPARATOR
Intervention: Control arm (opposite arm)
Number of subjects: 12
Study 17015541 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 12
Study 12580803 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice from doctors and MIEC (group B)
Number of subjects: 378
Study 12580803 — intervention group
Group type: COMPARATOR
Intervention: Advice from doctors only (group A)
Number of subjects: 378
Study 10885356 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine 31.25 mg
Number of subjects: 426
Study 10885356 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine 62.5 mg
Number of subjects: 426
Study 10885356 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine 125 mg
Number of subjects: 426
Study 10885356 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine 250 mg
Number of subjects: 426
Study 10885356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 426
Study 9112147 — intervention group
Group type: EXPERIMENTAL
Intervention: Irritable bowel syndrome group
Number of subjects: 31
Study 9112147 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 31
Study 8490010 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenomethionine (200 micrograms Se as Se‐enriched yeast)
Number of subjects: 33
Study 8490010 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenate (brewer's yeast mixed with selenate)
Number of subjects: 33
Study 8490010 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no added Se)
Number of subjects: 33
Study 3087915 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (30 or 50 micrograms ethinyl oestradiol and 150 micrograms levonorgestrel)
Number of subjects: 0
Study 3087915 — intervention group
Group type: EXPERIMENTAL
Intervention: Depo-medroxyprogesterone acetate (DMPA)
Number of subjects: 0
Study 3087915 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive pills
Number of subjects: 0
Study 3087915 — intervention group
Group type: COMPARATOR
Intervention: Control group (middle-income reference group)
Number of subjects: 0
Study 29863964 — intervention group
Group type: EXPERIMENTAL
Intervention: Male targets with anorexia nervosa (AN)
Number of subjects: 0
Study 29863964 — intervention group
Group type: EXPERIMENTAL
Intervention: Female targets with anorexia nervosa (AN)
Number of subjects: 0
Study 29863964 — intervention group
Group type: EXPERIMENTAL
Intervention: Male targets with bulimia nervosa (BN)
Number of subjects: 0
Study 29863964 — intervention group
Group type: EXPERIMENTAL
Intervention: Female targets with bulimia nervosa (BN)
Number of subjects: 0
Study 29438547 — intervention group
Group type: EXPERIMENTAL
Intervention: Online training for general practitioners (GPs) and an information booklet for parents
Number of subjects: 1009
Study 29438547 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1009
Study 29438547 — intervention group
Group type: EXPERIMENTAL
Intervention: Online training for GPs and an information booklet for parents
Number of subjects: 1009
Study 27619760 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-session school nurse-delivered cognitive-behavioral counseling intervention plus school-based after school exercise program
Number of subjects: 126
Study 27619760 — intervention group
Group type: COMPARATOR
Intervention: 12-session nurse contact with weight management information (control)
Number of subjects: 126
Study 25644388 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (2 mg)
Number of subjects: 12
Study 25644388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 25644388 — intervention group
Group type: EXPERIMENTAL
Intervention: Able-bodied subjects (no intervention)
Number of subjects: 12
Study 23625063 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel, cisplatin plus 5-FU (DCF)
Number of subjects: 501
Study 23625063 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin plus 5-FU with chemoradiotherapy (CF-RT)
Number of subjects: 501
Study 23625063 — intervention group
Group type: COMPARATOR
Intervention: cisplatin plus 5-FU (CF)
Number of subjects: 501
Study 20655766 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular corticosteroid injection (accuracy identified by fluoroscopy)
Number of subjects: 103
Study 20655766 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular corticosteroid injection (accuracy identified by palpation)
Number of subjects: 103
Study 18173610 — intervention group
Group type: EXPERIMENTAL
Intervention: Zycure (0.005% solasodine glycosides)
Number of subjects: 94
Study 18173610 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 94
Study 16723194 — intervention group
Group type: COMPARATOR
Intervention: 0 microg/kg THC (placebo)
Number of subjects: 20
Study 16723194 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 microg/kg THC
Number of subjects: 20
Study 16723194 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg/kg THC
Number of subjects: 20
Study 14573318 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 26
Study 14573318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 14573318 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant-free patients
Number of subjects: 26
Study 14573318 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant-treated patients
Number of subjects: 26
Study 10680784 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (5 mg/kg IV over 30 minutes)
Number of subjects: 16
Study 10680784 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 16
Study 9292253 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatment options that block calcium channels or inhibit the sodium-mediated calcium transporter to prevent axonal damage.
Number of subjects: 0
Study 8245335 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month exercise training program (n = 49)
Number of subjects: 95
Study 8245335 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 46)
Number of subjects: 95
Study 8245335 — intervention group
Group type: COMPARATOR
Intervention: Both groups (control and training)
Number of subjects: 95
Study 3535364 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin
Number of subjects: 100
Study 3535364 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical PGE2‐gel followed by intravenous oxytocin
Number of subjects: 100
Study 3535364 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical PGE2‐gel twice with a 12‐hour interval
Number of subjects: 100
Study 3535364 — intervention group
Group type: COMPARATOR
Intervention: Intracervical placebo gel twice with 12‐hour interval
Number of subjects: 100
Study 29166130 — intervention group
Group type: EXPERIMENTAL
Intervention: JetPeel-assisted topical minoxidil
Number of subjects: 30
Study 29166130 — intervention group
Group type: COMPARATOR
Intervention: Topical minoxidil monotherapy
Number of subjects: 30
Study 29166130 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 30
Study 27190009 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline
Number of subjects: 692
Study 27190009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 692
Study 25793947 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic toothbrush
Number of subjects: 40
Study 25793947 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 40
Study 22075447 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced education (one education session, plus 11 sessions of group education, individual discussions, and educational plays over six months)
Number of subjects: 204
Study 22075447 — intervention group
Group type: COMPARATOR
Intervention: Standard education (one education session and 5 follow up visits)
Number of subjects: 204
Study 20375907 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatments (BP-lowering agents)
Number of subjects: 221024
Study 20375907 — intervention group
Group type: EXPERIMENTAL
Intervention: For each 5-mmHg reduction in SBP
Number of subjects: 221024
Study 20375907 — intervention group
Group type: EXPERIMENTAL
Intervention: For each 2-mmHg reduction in DBP
Number of subjects: 221024
Study 20375907 — intervention group
Group type: EXPERIMENTAL
Intervention: Different BP reduction of at least 4.6 mmHg in SBP or at least 2.2 mmHg in DBP
Number of subjects: 221024
Study 17985242 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pantoprazole 80 mg loading dose over 5 min, followed by 8 mg/h intravenous infusion for 72 h, then 40 mg orally once a day for 4 days.
Number of subjects: 6
Study 17985242 — intervention group
Group type: COMPARATOR
Intervention: Control group received 40 mg pantoprazole intravenously once a day for 72 h, then orally once a day for 4 days.
Number of subjects: 6
Study 16021478 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus antiemetic medication
Number of subjects: 11
Study 16021478 — intervention group
Group type: COMPARATOR
Intervention: Anti-emetic medication alone
Number of subjects: 11
Study 12667379 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole Amoxicillin Clarythromycin (OAC) triple therapy
Number of subjects: 552
Study 12667379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 552
Study 10894441 — intervention group
Group type: EXPERIMENTAL
Intervention: COER-verapamil
Number of subjects: 1055
Study 10894441 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/Atenolol
Number of subjects: 1055
Study 10894441 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (monotherapy)
Number of subjects: 1055
Study 10894441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1055
Study 10894441 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine GITS
Number of subjects: 1055
Study 8733877 — intervention group
Group type: EXPERIMENTAL
Intervention: iv metoclopramide (MCP) at 30 micrograms/kg/h over 48 h
Number of subjects: 11
Study 8733877 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 56 h
Number of subjects: 11
Study 8733877 — intervention group
Group type: COMPARATOR
Intervention: Baseline (ad libitum food)
Number of subjects: 11
Study 8733877 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 56 h + iv MCP during the final 48 h
Number of subjects: 11
Study 1706531 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES 40/0.5)
Number of subjects: 55
Study 1706531 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer solution (LRS)
Number of subjects: 55
Study 6293715 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (20 mg/kg every six hours)
Number of subjects: 98
Study 6293715 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin (1 mg/kg every eight hours) plus Clindamycin (5 mg/kg every six hours)
Number of subjects: 98
Study 6293715 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin plus Clindamycin
Number of subjects: 98
Study 30928863 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg quetiapine daily for 8 weeks
Number of subjects: 60
Study 28483885 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based vestibular rehabilitation program (Balance Retraining)
Number of subjects: 296
Study 28483885 — intervention group
Group type: COMPARATOR
Intervention: Usual primary care
Number of subjects: 296
Study 25925036 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block (ISPB) with 20 mL 0.25% bupivacaine
Number of subjects: 3
Study 25925036 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular (IA) administration with 20 mL 0.25% bupivacaine
Number of subjects: 3
Study 25925036 — intervention group
Group type: COMPARATOR
Intervention: Control group (no block performed)
Number of subjects: 3
Study 23106905 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAT; aspirin and prasugrel)
Number of subjects: 40
Study 23106905 — intervention group
Group type: COMPARATOR
Intervention: Triple antiplatelet therapy (TAT; aspirin, clopidogrel, cilostazol)
Number of subjects: 40
Study 21798863 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 × 25 g/day whey protein (PRO)
Number of subjects: 31
Study 21798863 — intervention group
Group type: COMPARATOR
Intervention: maltodextrin (CARB)
Number of subjects: 31
Study 19326422 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (400 microg) combined with intravenous patient-controlled analgesia (IV-PCA)
Number of subjects: 40
Study 19326422 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (IV-PCA) alone
Number of subjects: 40
Study 16964364 — intervention group
Group type: EXPERIMENTAL
Intervention: AsthmaCritic (intervention group)
Number of subjects: 40
Study 16964364 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 40
Study 15118182 — intervention group
Group type: COMPARATOR
Intervention: US patients
Number of subjects: 1604
Study 15118182 — intervention group
Group type: COMPARATOR
Intervention: Canadian patients
Number of subjects: 1604
Study 11722037 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-managed anticoagulation
Number of subjects: 100
Study 11722037 — intervention group
Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 100
Study 9394314 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulodexide (600 lipoproteinlipase releasing units by i.m. route, 5 days/week for 3 weeks)
Number of subjects: 36
Study 9394314 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching i.m. placebo, 5 days/week for 3 weeks)
Number of subjects: 36
Study 8788011 — intervention group
Group type: EXPERIMENTAL
Intervention: 65% random sample of 648 individuals
Number of subjects: 1000
Study 8788011 — intervention group
Group type: COMPARATOR
Intervention: 65% enriched sample with oversampling of individuals with high levels of Q1
Number of subjects: 1000
Study 2365900 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive psychotherapy
Number of subjects: 91
Study 2365900 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief behavioral psychotherapy
Number of subjects: 91
Study 2365900 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psychodynamic psychotherapy
Number of subjects: 91
Study 2365900 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttreatment depression-free patients
Number of subjects: 91
Study 432541 — intervention group
Group type: EXPERIMENTAL
Intervention: Brush cytology
Number of subjects: 195
Study 432541 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic biopsy
Number of subjects: 195
Study 30985829 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone
Number of subjects: 0
Study 28844213 — intervention group
Group type: EXPERIMENTAL
Intervention: R. ribes syrup
Number of subjects: 150
Study 28844213 — intervention group
Group type: COMPARATOR
Intervention: Placebo syrup
Number of subjects: 150
Study 28844213 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 150
Study 24596359 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored exercise intervention
Number of subjects: 25
Study 21749526 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct buprenorphine/naloxone (BNX) induction
Number of subjects: 187
Study 21749526 — intervention group
Group type: COMPARATOR
Intervention: Indirect buprenorphine (BPN)‐to‐BNX induction
Number of subjects: 187
Study 21749526 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (direct and indirect induction)
Number of subjects: 187
Study 21749526 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct induction
Number of subjects: 187
Study 21749526 — intervention group
Group type: COMPARATOR
Intervention: Indirect induction
Number of subjects: 187
Study 20237186 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmar fixed‐angle plating (n=50)
Number of subjects: 103
Study 20237186 — intervention group
Group type: COMPARATOR
Intervention: Mixed pinning (n=53)
Number of subjects: 103
Study 17939093 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic-Ceramic bearing
Number of subjects: 66
Study 17939093 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic-Polyethylene bearing
Number of subjects: 66
Study 17939093 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 66
Study 15823788 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program (16 weeks, 3 times per week of 30 min of moderate intensity exercise)
Number of subjects: 69
Study 15823788 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Number of subjects: 69
Study 15823788 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 69
Study 12521274 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal Continuous Positive Airway Pressure (NCPAP)
Number of subjects: 37
Study 12521274 — intervention group
Group type: COMPARATOR
Intervention: Oxygen mask treatment
Number of subjects: 37
Study 9312762 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 150
Study 9312762 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CTX)
Number of subjects: 150
Study 9312762 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (PRE)
Number of subjects: 150
Study 9312762 — intervention group
Group type: COMPARATOR
Intervention: Non-steroidal anti-inflammatory drugs (NSAID)
Number of subjects: 150
Study 8339132 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day of slow release diclofenac
Number of subjects: 89
Study 8339132 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 89
Study 3549420 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (100-150 mg/day)
Number of subjects: 29
Study 3549420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 3549420 — intervention group
Group type: COMPARATOR
Intervention: Trazodone and Placebo
Number of subjects: 29
Study 31610409 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal sleep (8.5 hours)
Number of subjects: 14
Study 31610409 — intervention group
Group type: COMPARATOR
Intervention: Restricted sleep (4.5 hours)
Number of subjects: 14
Study 29987576 — intervention group
Group type: EXPERIMENTAL
Intervention: sGFP(S65T) gene expression in Pd
Number of subjects: 0
Study 29939697 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced acute mild arterial hypertension
Number of subjects: 0
Study 29939697 — intervention group
Group type: COMPARATOR
Intervention: Control group (no induced hypertension)
Number of subjects: 0
Study 25450369 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation
Number of subjects: 20
Study 25450369 — intervention group
Group type: COMPARATOR
Intervention: Passive smoking
Number of subjects: 20
Study 22185623 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal Sound Stimulation (MSS)
Number of subjects: 14
Study 22185623 — intervention group
Group type: COMPARATOR
Intervention: Routine Hospital Sounds (RHS)
Number of subjects: 14
Study 20552569 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-likelihood analysis
Number of subjects: 0
Study 20552569 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete case analysis
Number of subjects: 0
Study 20552569 — intervention group
Group type: EXPERIMENTAL
Intervention: Single imputation techniques (two analyses)
Number of subjects: 0
Study 20552569 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern-mixture models
Number of subjects: 0
Study 20552569 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 0
Study 18821646 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus activity strategy training (Ex + AST)
Number of subjects: 54
Study 18821646 — intervention group
Group type: COMPARATOR
Intervention: Exercise plus health education (Ex + Ed)
Number of subjects: 54
Study 15683356 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged care nurse intervention
Number of subjects: 224
Study 15683356 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 224
Study 12111446 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin (Cere), 30 mL injected intravenously, five days per week for four weeks
Number of subjects: 192
Study 12111446 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin (Cere)
Number of subjects: 192
Study 12111446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 9923490 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerokeratoplasty
Number of subjects: 20
Study 9923490 — intervention group
Group type: COMPARATOR
Intervention: Total penetrating keratoplasty
Number of subjects: 20
Study 7589029 — intervention group
Group type: EXPERIMENTAL
Intervention: mizolastine 10 mg
Number of subjects: 18
Study 7589029 — intervention group
Group type: EXPERIMENTAL
Intervention: cetirizine 10 mg
Number of subjects: 18
Study 7589029 — intervention group
Group type: EXPERIMENTAL
Intervention: ethanol
Number of subjects: 18
Study 7589029 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 2012082 — intervention group
Group type: COMPARATOR
Intervention: 5 mg aerosol pentamidine biweekly
Number of subjects: 175
Study 2012082 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg aerosol pentamidine biweekly
Number of subjects: 175
Study 2012082 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg aerosol pentamidine biweekly
Number of subjects: 175
Study 7084029 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole (TMP/SMX) 6.8/34 mg/kg/d divided into twice daily doses for six months
Number of subjects: 21
Study 7084029 — intervention group
Group type: COMPARATOR
Intervention: Control group (acute treatment only)
Number of subjects: 21
Study 30324827 — intervention group
Group type: COMPARATOR
Intervention: Exercise Group (EG)
Number of subjects: 0
Study 30324827 — intervention group
Group type: COMPARATOR
Intervention: Laser Group (LG)
Number of subjects: 0
Study 30324827 — intervention group
Group type: COMPARATOR
Intervention: Laser + Exercise Group (LEG)
Number of subjects: 0
Study 29937161 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective neck dissection (END)
Number of subjects: 221